Document:

EX-10.1

 Exhibit 10.1 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

This Amended and Restated Investors’ Rights Agreement is made as of January 20, 2015 (the “Effective Date”)
by and among Allergen Research Corporation, a Delaware corporation (the “Company”), each of the investors listed on Annex A attached hereto, each of which is referred to in this Agreement as an “Investor” and
any additional Investor (as defined in the Purchase Agreement, as hereinafter defined) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 

WHEREAS, the Company and certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even date
herewith (as may be amended from time to time, the “Purchase Agreement”), pursuant to which such Investors are purchasing shares of Series B Preferred Stock. 

WHEREAS, the Company and certain of the Investors (the “Prior Investors”) have previously entered into that certain
Investors’ Rights Agreement dated as of February 8, 2013, as amended on April 11, 2013 (the “Prior Agreement”), for the purpose of granting certain registration and other rights to such Prior Investors. 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in
the Company pursuant to the Purchase Agreement, the Investors and the Company are entering into this Agreement to grant certain registration and other rights to the Investors and to amend, restate and otherwise supersede in its entirety the Prior
Agreement as set forth herein.  
 WHEREAS, any term of the Prior Agreement may be amended and the observance of any term
thereof may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least a majority of the Registrable Securities (as defined in the
Prior Agreement) outstanding.  
 WHEREAS, the Company has executed this Agreement, and the Prior Investors who are
signatories to this Agreement hold at least that number of shares necessary to effect an amendment of the Prior Agreement. The Prior Agreement is superseded and replaced by this Agreement, including with respect to those Prior Investors who are not
signatories to this Agreement. 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. 

 1.2 “Common Stock” means shares of the Company’s Common
Stock, par value $0.0001 per share. 
 1.3 “Competitor” means a Person engaged, directly or indirectly
(including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the development and/or commercialization of oral immunotherapy treatments or diagnostics
for the management of food allergy, but will not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than 20% of the outstanding equity of any Competitor and does not, nor do any of
its Affiliates, have a right to designate any members of the Board of any Competitor. 
 1.4 “Damages” means
any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect
thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged
violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities
law. 
 1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or
exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.6
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.7 “Excluded Registration” means (i) a registration relating to the sale of securities to employees of
the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information
as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered. 
 1.8 “Form S-1” means such form under the Securities Act as in effect on
the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

  
 2 

 1.9 “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.10 “GAAP” means generally accepted accounting principles in the United States. 

1.11 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.12 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.13 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.14 “IPO” means the Company’s first underwritten public offering of its Common Stock
under the Securities Act. 
 1.15 “Key Employee” means any executive-level employee (including division
director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.16 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates,
holds at least 600,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.17 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities, except for
(i) Excluded Securities, as defined in the Company’s Third Amended and Restated Certificate of Incorporation, as amended and (ii) equity securities issued pursuant to the Purchase Agreement. 

1.18 “Person” means any individual, corporation, partnership, trust, limited liability company, association or
other entity. 
 1.19 “Preferred Stock” means the Series A Preferred Stock and the Series B Preferred
Stock. 
 1.20 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion
of the Preferred Stock; (ii) any Common Stock, or any Common Stock 

  
 3 

 
issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any Common
Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses
(i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes
of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.21 “Registrable Securities then outstanding” means the number of shares determined by adding the number of
shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.22 “Restated Certificate” means the Company’s Third Amended and Restated Certificate of Incorporation,
as amended. 
 1.23 “Restricted Securities” means the securities of the Company required to bear the legend
set forth in Section 2.12(b) hereof. 
 1.24 “SEC” means the Securities and Exchange Commission. 

1.25 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.26 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.27 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.28 “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

1.29 “Series A Director” means the director of the Company that the holders of record of the Series A
Preferred Stock are entitled to elect pursuant to the Restated Certificate. 
 1.30 “Series B Directors”
means the directors of the Company that the holders of record of the Series B Preferred Stock are entitled to elect pursuant to the Restated Certificate. 

1.31 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001
per share. 

  
 4 

 1.32 “Series B Preferred Stock” means shares of the
Company’s Series B Preferred Stock, par value $0.0001 per share. 
 2. Registration Rights. 

2.1 Demand Registration. 

(a) Form S-l Demand. If at any time after the earlier of (i) five (5) years after the date of this Agreement
or (ii) one (1) year after the effective date of the registration statement for the IPO, the Company receives a request from Holders of fifty percent (50%) of the Registrable Securities then outstanding that the Company file a Form
S-l registration statement with respect to the Registrable Securities then outstanding and if the anticipated aggregate offering price is at least $3,000,000.00, then the Company will (x) within ten (10) days after the date such request is
given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the
Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such
registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and
Section 2.3. 
 (b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement,
the Company receives a request from Holders of at least twenty-five (25%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders
having an anticipated aggregate offering price, net of Selling Expenses, of at least $1,000,000.00, then the Company will (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the
Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject
to the limitations of Section 2.1(c) and Section 2.3. 
 (c) Notwithstanding the foregoing obligations, if the
Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board it would be materially
detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would
(i) materially interfere with a significant acquisition, corporate reorganization, or 

  
 5 

 
other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;
or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company will have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof will be tolled correspondingly, for a period of not more than one hundred eighty (180) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once
in any twelve (12) month period; and provided further that the Company will not register any securities for its own account or that of any other stockholder during such one hundred eighty (180) day period other than an
Excluded Registration. 
 (d) The Company will not be obligated to effect, or to take any action to effect, any registration
pursuant to Section 2.1(a)(i) during the period that is ninety (90) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a
Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two
registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b).
The Company will not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b)(i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of,
and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to
become effective; or (ii) if the Company has effected two registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration will not be counted as
“effected” for purposes of this Section 2(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay
the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement will be counted as “effected” for purposes of this
Section 2.1(d). 
 2.2 Company Registration. If the Company proposes to register (including, for this purpose, a
registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the
Company will, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company will, subject to the provisions of
Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be 

  
 6 

 
included in such registration. The Company will have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such
registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration will be borne by the Company in accordance with Section 2.6.

 2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they will so advise the Company as a part of their request made pursuant to Section 2.1, and the Company will include such information in the Demand Notice. The underwriter(s) will be selected by a majority
in interest of the Initiating Holders and will be reasonably acceptable to the Company. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration will be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting will (together with
the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3. if the underwriter(s)
advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders will so advise all Holders of Registrable Securities that otherwise would be underwritten
pursuant hereto, and the number of Registrable Securities that may be included in the underwriting will be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the
number of Registrable Securities owned by each Holder or in such other proportion as will mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in
such underwriting will not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number
of shares allocated to any Holder to the nearest 100 shares. 
 (b) In connection with any offering involving an underwriting
of shares of the Company’s capital stock pursuant to Section 2.2, the Company will not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as
agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including
Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success
of the offering, then the Company will be required to include in the 

  
 7 

 
offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the
offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering will be allocated among the
selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as will mutually be agreed to by all such selling Holders. To facilitate the allocation of
shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event will (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be
reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described
above and no other stockholder’s securities are included in such offering For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or
corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for
the benefit of any of the foregoing Persons, will be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” will be based upon the aggregate number of Registrable Securities owned
by all Persons included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of
Section 2.1, a registration will not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included. 
 2.4
Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company will, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially
reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one
hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period will be extended for a
period of time equal to the period 

  
 8 

 
the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of
any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period will be extended for up to sixty
(60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in
connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by
the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under
such other securities or blue-sky laws of such jurisdictions as will be reasonably requested by the selling Holders; provided that the Company will not be required to qualify to do business or to file a general consent to service of process
in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement,
in usual and customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to
cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company
are then listed; 
 (g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this
Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant
to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and
cause the 

  
 9 

 
Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each
case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company
amend or supplement such registration statement or prospectus. 
 In addition, the Company will ensure that, at all times after any
registration statement covering a public offering of securities of the Company under the Securities Act will have become effective, its insider trading policy will provide that the Company’s directors may implement a trading program under Rule
10b5-l of the Exchange Act. 
 2.5 Furnish Information. It will be a condition precedent to the obligations of the
Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder will furnish to the Company such information regarding itself, the Registrable Securities held by it, and
the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations,
filings, or qualifications pursuant to Section 2. including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements,
together not to exceed $25,000.00, of one counsel for the selling Holders (“Selling Holder Counsel”), will be borne and paid by the Company; provided, however, that the Company will not be required to pay for any
expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling
Holders will bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one
registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business or prospects of
the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not
forfeit their right to one registration pursuant to Subsection 2.1(a) or Subsection 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 will be borne and paid by the Holders pro
rata on the basis of the number of Registrable Securities registered on their behalf. 

  
 10 

 2.7 Delay of Registration. No Holder will have any right to obtain or seek
an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:

 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners,
members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably
incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a)
will not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent will not be unreasonably withheld, nor will the Company be liable for any Damages to the
extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person
expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally
and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal
counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages,
in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection
with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from
which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) will not apply to amounts paid in settlement of any such claim or proceeding if such
settlement is effected without 

  
 11 

 
the consent of the Holder, which consent will not be unreasonably withheld; and provided further that in no event will the aggregate amounts payable by any Holder by way of
indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the
indemnifying party notice of the commencement thereof. The indemnifying party will have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) will have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be
inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the
commencement of any such action will relieve such indemnifying party of any liability to the indemnified party under this Section 2.8 to the extent that such failure materially prejudices the indemnifying party’s ability to defend such
action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction
and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses,
claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified
party will be determined by reference to, among other things, 

  
 12 

 
whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required
to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event will a Holder’s liability
pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder),
except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that
the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement
will control. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection with the
underwritten public offering, the obligations of the Company and Holders under this Section 2.8 will survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise will survive the
termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company will: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at
all times after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially
reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the
extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such 

  
 13 

 
reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent
annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the
selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company will not,
without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would provide to such holder the
right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all
shares of Registrable Securities that they wish to so include; provided that this limitation will not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 

2.11 “Market Stand-off” Agreement. Each Holder will not, without the prior written consent of the managing
underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a registration
statement on Form S-l, and ending on the date specified by the Company and the managing underwriter (such period not to exceed (x) one hundred eighty (180) days, or such other period as may be required to accommodate regulatory
restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any
successor provisions or amendments thereto, (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration
statement on Form S-1 for the IPO or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in
clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 will apply only to the IPO, will not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in
writing by the restrictions set forth herein, and provided further that any such transfer will not involve a disposition for value, and will be applicable to the Holders only if all officers, directors and all stockholders individually owning more
than one percent (1%)

  
 14 

 
of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in
connection with such registration are intended third-party beneficiaries of this Section 2.11 and will have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder will execute such
agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. 

2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities will not be sold, pledged, or otherwise transferred, and the Company
will not recognize and will issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with
the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate or instrument representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger,
consolidation, or similar event, will (unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND
THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in
its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

  
 15 

 (c) The holder of each certificate representing Restricted Securities, by
acceptance thereof, will comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act
covering the proposed transaction, the Holder thereof will give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice will describe the manner and circumstances of the proposed sale, pledge,
or transfer in sufficient detail and, if reasonably requested by the Company, will be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who will, and whose legal opinion will, be reasonably satisfactory
to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge,
or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company
to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities will be entitled to sell, pledge, or transfer
such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144
or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each
certificate or instrument evidencing the Restricted Securities transferred as above provided will bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such
certificate will not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable
Securities in any registration pursuant to Section 2.1 or Section 2.2 will terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such
Holder’s shares without limitation during a three-month period without registration; and 
 (c) the fifth anniversary of
the IPO. 
 3. Information and Observer Rights. 

  
 16 

 3.1 Delivery of Financial Statements. The Company will deliver to each
Major Investor, unless the Board has determined in good faith that such Major Investor is a Competitor: 
 (a) as soon as
practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year and (iii) a
statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants selected by the Company; 

(b) as soon as practicable, but in any event within thirty (30) days after the end of each of the first three
(3) quarters of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all
prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income
statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be
subject to normal year- end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(d) prior to the beginning of each fiscal year, a copy of the annual budget for the Company as approved by the Board, and as
soon as practicable, any substantive amendments to such budget during the relevant year as approved by the Board. 
 If, for
any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections will be the consolidated and consolidating
financial statements of the Company and all such consolidated subsidiaries. 
 Notwithstanding anything else in this
Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of
a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 will be reinstated
at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

  
 17 

 3.2 Inspection. The Company will permit each Major Investor or an
authorized representative of such Major Investor (provided that the Board has not reasonably determined that such Major Investor is a Competitor), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its
books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that
the Company will not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable
confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Observer Rights. As long as Food Allergy Research & Education, Inc. owns at least 588,235 shares of Common
Stock of the Company (including shares of Common Stock issued or issuable upon conversion of Preferred Stock), which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like, if Food
Allergy Research & Education, Inc. does not have a designee on the Board, the Company will invite a representative of Food Allergy Research & Education, Inc. to attend all meetings of its Board in a nonvoting observer capacity and,
in this respect, will give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative will agree to hold in confidence and trust and
to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if
access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its
representative is a Competitor of the Company. As long as Longitude Venture Partners II, L.P. (together with its affiliated entities, “Longitude”) owns at least 588,235 shares of Common Stock of the Company (including shares of
Common Stock issued or issuable upon conversion of Preferred Stock), which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like, the Company will invite a representative of
Longitude to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, will give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided,
however, that such representative will agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any
information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in
disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company. As long as Foresite Capital Fund II, L.P. (together with its affiliated entities, “Foresite”) owns at
least 720,000 shares of Common Stock of the Company (including shares of Common Stock issued or issuable upon conversion of Preferred Stock), which number is subject to appropriate adjustment for all stock splits, dividends, combinations,
recapitalizations and 

  
 18 

 
the like, the Company will invite a representative of Foresite to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, will give such representative copies of
all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative will agree to hold in confidence and trust and to act in a fiduciary manner with respect to all
information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such
meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company. 

3.4 Termination of Information and Observer Rights. The covenants set forth in Section 3.1, Section 3.2 and
Section 3.3 will terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of
the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. 

3.5 Confidentiality. Each Investor will keep confidential and will not disclose, divulge, or use for any purpose (other
than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such
confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without
use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided,
however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the
Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any Affiliate, partner, member, stockholder,
or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or
(iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws,
if the Company proposes to offer or sell any New Securities, the Company will first offer such New Securities to each Investor. An Investor will be entitled to apportion the right of first offer hereby granted to it, in such proportions as it deems
appropriate, among itself and its Affiliates. 

  
 19 

 (a) The Company will give notice (the “Offer Notice”) to each
Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect to
purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as
applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company will promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a
“Fully Exercising Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the
Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but that were not subscribed for by the Investors which is equal to
the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to
the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such
unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) will occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section
4.1(c). 
 (c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided
in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b) offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons
at a price at least, and upon terms no more favorable to the offered than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not
consummated within thirty (30) days of the execution thereof, the right provided hereunder will be deemed to be revived and such New Securities will not be offered unless first reoffered to the Investors in accordance with this
Section 4.1. 

  
 20 

 (d) The right of first offer in this Section 4.1 will not be applicable to
(i) Excluded Securities (as defined in the Restated Certificate); (ii) shares of Common Stock issued in the IPO; (iii) the issuance of shares of Preferred Stock to additional purchasers pursuant to the Purchase Agreement; and
(iv) any New Securities which the Board exempts from the right of first offer in this Section 4.1 and reserves to be offered to and subscribed by third parties as new investors in the Company. 

(e) The right of first offer set forth in this Section 4.1 will terminate with respect to any Investor who fails to
purchase, in any Qualified Financing subject to this Section 4.1, that portion of the New Securities which equals (i) the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or
exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred
Stock and other Derivative Securities). For purposes of this Agreement, a “Qualified Financing” shall mean the issuance and sale by the Company of a newly-authorized series of Preferred Stock to investors for aggregate gross
proceeds to the Company of not less than $10 million in a round of equity financing led by an institutional investor. 
 4.2
Termination. The covenants set forth in Section 4.1 will terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(d) of the Exchange Act, (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, or (iv) upon the completion of a transaction in which any shares of Preferred
Stock are converted into any other property or security other than Common Stock, whichever event occurs first and, as to each Investor, in accordance with Section 4.1(e). 

5. Additional Covenants. 

5.1 Insurance. To the extent such insurance is not already in force, the Company will use its commercially reasonable
efforts to obtain, within ninety (90) days of the date hereof, from financially sound and reputable insurers Directors and Officers liability insurance and term “key-person” insurance on each employee and officer deemed necessary by
the Board, in an amount and on terms and conditions satisfactory to the Board and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board determines that such insurance should be
discontinued. The key-person policy will name the Company as loss payee, and neither policy will be cancelable by the Company without prior approval by the Board. The Company has no key man insurance or Directors and Officers liability insurance in
place as Of the Effective Date. 
 5.2 Service Provider Agreements. The Company will cause each person now or
hereafter employed by it or by a subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights
assignment agreement. 

  
 21 

 5.3 Service Provider Stock. Unless otherwise approved by the Board, all
future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof will be required to execute restricted stock or option agreements, as
applicable, providing for vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting
in equal monthly installments over the following thirty- six (36) months of service. 
 5.4 Matters Requiring
Investor Director Approval. So long as the holders of Preferred Stock are entitled to elect the Series A Director and at least one (1) Series B Director, the Company will not, without approval of the Board, by the affirmative vote of at
least a majority of the then serving members of the Board and including in such majority the affirmative vote of the Series A Director and at least one (1) Series B Director (the “Required Board Approval”): 

(a) Any actions set forth in Section 3.3 of Part B of Article FOURTH of the Restated Certificate; 

(b) All Company budgets and operating plans; 

(c) All preclinical trial and clinical trial plans; 

(d) Any amendments, including any increase or decrease in the share reserve thereunder, of the Company’s then-current
equity incentive plan, and the creation of and reservation of shares under, and any amendments to, all other Company equity incentive plans; 

(e) The issuance of any Excluded Securities; 

(f) Any New Securities which the Board exempts from the right of first offer in Section 4.1; 

(g) Any license of all or substantially all of the intellectual property assets of the Company; or 

(h) Take any action for the Company to: 

(i) Make any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or
other entity unless it is wholly owned by the Company, or the disposition of subsidiary stock or all or substantially all of any subsidiary assets; 

(ii) Make any loan or advance to any person, including, any employee or director, except advances and similar expenditures in
the ordinary course of business or under the terms of an employee stock or option plan approved by the Board; 

  
 22 

 (iii) Guarantee any indebtedness except for trade accounts of the Company or any
subsidiary arising in the ordinary course of business; 
 (iv) Make any investment other than in accordance with the
investment policy approved by the Board; 
 (v) Make any single expenditure that is not included in the budget and is in
excess of a threshold amount to be determined by the Board; 
 (vi) Incur any aggregate indebtedness not already included in
a budget that has been approved by the Required Director Approval that is in excess of $100,000.00; 
 (vii) Exceed the
expenses contemplated in the Board- approved budget for such year that is in excess of a threshold amount to be determined by the Board; 

(viii) Approve any material revisions to the then-current Business Plan of the Company; 

(ix) Enter into or be a party to any material transaction with any affiliate of the Company or any director, officer or
employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934, as amended) of any such person; 

(x) Hire, fire, or change the compensation of the executive officers of the Company, including approving any option grants;

 (xi) Change the principal business of the Company, or make any material change in the Company’s then-current line(s)
of business or business model, or enter any new line(s) of business, or exit any then-current line of business; 
 (xii)
Sell, transfer, assign, license, pledge or encumber technology or intellectual property of the Company, other than licenses granted in the ordinary course of business; 

(xiii) Make any material (greater than 20% ownership) investment into, or enter into any joint venture with, or acquire, any
third party, or acquire all or substantially all of any third party’s assets, or otherwise enter into any corporate strategic relationship involving the payment, contribution or assignment by the Company or to the Company of assets greater than
$100,000.00; or 

  
 23 

 (xiv) Prepare or file for an initial public offering by the Company. 

5.5 Board Matters. Unless otherwise determined by a Required Director Approval, the Board will meet at least quarterly.
The Company will reimburse the nonemployee directors and representatives of Investors invited to attend meetings of the Board in a nonvoting observer capacity for all reasonable out-of-pocket travel expenses incurred (consistent with the
Company’s travel policy) in connection with attending meetings of the Board. Any committee of the Board will consist of the Series A Director and at least one (1) Series B Director, unless otherwise agreed by such affected director. Each
of the Series B Director nominated by Foresite and the Series B Director nominated by Aisling Capital III, LP (“Aisling”) has the right to be on any committee. 

5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any
other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision will be made so that the successors and assignees of the Company assume the obligations of the
Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Restated Certificate, or elsewhere, as the case may be. 

5.7 Termination of Covenants. The covenants set forth in this Section 5, except for Section 5.6, will
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act; or
(iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. 

5.8 Use of Proceeds from Sale of Series B Preferred Stock. The Company shall use an aggregate of not less than
$7,500,000 of the proceeds from the sale of Series B Preferred Stock pursuant to the Purchase Agreement to repurchase shares of outstanding Series A Preferred Stock. 

6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a
Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family
Members; or (iii) after such transfer, holds at least ten percent (10%) of the total outstanding shares of Registrable Securities previously held by the Holder; if (x) the Company is, within a reasonable time after such transfer,
furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to
be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes 

  
 24 

 
of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a
Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member will be aggregated together and with those of the transferring Holder; provided further that all
transferees who would not qualify individually for assignment of rights will have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this
Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement will be governed by the internal laws of the State of California, without regard to
conflict of laws principles. 
 6.3 Counterparts. This Agreement may be executed in two or more counterparts, each of
which will be deemed an original, but all of which together will constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered will
be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
 6.4 Titles and
Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 

6.5 Notices. All notices and other communications given or made pursuant to this Agreement will be in writing and will
be deemed effectively given upon the earliest of (a) personal delivery to the party to be notified, including delivery by a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written
verification of receipt, or (b) when sent, if sent during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, by electronic mail, or by facsimile if the party to
whom such notice is sent shows a facsimile number below its signature hereon or if such party notifies all of the other parties, subsequent to the Effective Date, in the manner specified herein, of a facsimile number for such party, and in each case
without failure of transmission. Notices hereunder may not be sent by mail. All communications will be sent to the respective parties at their address as set forth below their signature on the signature page hereof, or to such email address,
facsimile number or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy will also be sent to Patrick A. Pohlen and Brian J. Cuneo, Latham & Watkins
LLP, 140 Scott Drive, Menlo Park, CA 94025, facsimile [***], email [***] and [***]. 

  
 25 

 6.6 Amendments and Waivers. Any term of this Agreement may be amended and
the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least a majority of the
Registrable Securities then outstanding; provided that Section 5.4 and Section 5.5 may be amended or waived with written consent of each of Longitude, Foresite and Aisling (for so long as such Investor has designated a director to the
Board); provided further that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of
Section 2.12(c) will be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this
Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in
the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction will be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact
that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company will give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent
in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 will be binding on all parties hereto, regardless of whether any such party has consented thereto. No
waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, will be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision will be reformed and construed so that it
will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares
of Registrable Securities held or acquired by Affiliates will be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate. 
 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein,
if the Company issues additional shares of Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this
Agreement, and thereafter will be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors will be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor
has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

  
 26 

 6.10 Entire Agreement. This Agreement (including all Annexes hereto)
constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties, or among certain of
the parties, including without limitation the Prior Agreement, is expressly canceled as of the Effective Date. 
 6.11
Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of California and to the jurisdiction of the United States District Court for the District of Northern California
for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of
California or the United States District Court for the District of Northern California, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is
not subject personally to the jurisdiction of the above- named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or
proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 
 WAIVER
OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER. HEREOF OR THEREOF. THE SCOPE OF
THIS WAIVER IS INTENDED TO BE ALL- ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE),
BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND
REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL 

6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this
Agreement, upon any breach or default of any other party under this Agreement, will impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor will it be construed to be a waiver of or acquiescence to any such breach or
default, or to any similar breach or default thereafter occurring, nor will any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement
or by law or otherwise afforded to any party, will be cumulative and not alternative. 

  
 27 

 6.13 Acknowledgment. The Company acknowledges that the Investors are in
the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of
the Company. Nothing in this Agreement will preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company.

 6.14 Counting Of Time. Whenever days are to be counted under this Agreement, the first day will not be counted and
the last day will be counted, provided that if any day on which a period specified in this Agreement would otherwise terminate falls on a weekend or on a federal or Delaware or California State holiday, then that day will be ignored for purposes of
counting time hereunder. 
 6.15 Several Liability. The obligations of the Investors will be several and not joint.

 (Signature page follows) 

  
 28 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

									
	ALLERGEN RESEARCH CORPORATION				INVESTORS:
				
	By:		 /s/ Stephen G. Dilly, Ph.D.
				 FOOD ALLERGY RESEARCH &

EDUCATION, INC.

	Name:		Stephen G. Dilly, Ph.D.						
	Title:		Chief Executive Officer				By:		/s/ James R. Baker, Jr. MD
	Address: 		2000 Alameda de las Pulgas,						James R. Baker, Jr., MD
			Suite 161						Chief Executive Officer
			San Mateo, CA 94403				Address: Attention: James R. Baker, Jr., MD
	Facsimile:         [***]						 515 Madison Avenue

	Email:   [***]						 Suite 1912

									 New York, NY 10022

							Facsimile: [***]
							Email: [***]
				
							SUNSHINE CHARITABLE FOUNDATION
					
							By:		 /s/ David R. Popovich

							Name: David R. Popovich
							Title: Director
							Address: 225 East Deerpath Road
							               Suite 210
							               Lake Forest, IL 60045
							Facsimile: [***]
							Email: [***]
				
							WINCHESTER PARTNERS, LP
					
							By:		 /s/ Michael Sacks

							Name: Michael Sacks
							Title: Managing Member of Winchester Managers LLC, General Partner of Winchester Partners, LP
							Address: 1850 Second Street
							               Suite 201
							               Highland Park, IL 60035
							 Facsimile: [***]
 Email:
[***]

									
							JOHN J. HANNAN FAMILY TRUST
					
							By:		 /s/ Judith Hannan

							Name: Judith Hannan
							Title: Trustee
							Address: 1133 Fifth Avenue
							               New York, NY 10128
							 Facsimile: [***]
 Email
[***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

									
							INVESTORS:
				
							 LONGITUDE VENTURE PARTNERS II, L.P.,

A Delaware limited partnership

				
							By: Longitude Capital Partners II, LLC, a Delaware limited liability company Its General Partner
					
							    By:		 /s/ Patrick Enright

							    Name: Patrick Enright
							    Title: Managing Member
				
							 800 El Camino Real, Suite 220
 Menlo
Park, CA 94025
  
 Phone: [***]

FAX: [***]
  

[***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

									
							INVESTORS:
				
							EXPLORE HOLDINGS LLC
					
							By:		 /s/ Paul Dauber

							Name: Paul Dauber
							Title: Manager
							Address: Attention: Erica Derout
							                PO Box 94314

               Seattle, WA 98124

Email: [***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

									
							INVESTORS:
				
							FORESITE CAPITAL FUND II, L.P.
					
							By:		Foresite Capital Management II, LLC,
							Its:		General Partner
					
							By:		 /s/ Dennis D. Ryan

							 Name:     Dennis D. Ryan

Title:       CFO

					
							Address:		  

									  

				
							 Facsimile: [***]
 Email:
      [***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	AISLING CAPITAL III, LP
		
	By:		 /s/ Lloyd Appel

	 Name: Lloyd Appel
 Title:
CFO

	
	 Aisling Capital III, L.P.
 888
Seventh Avenue, 30th Floor
 New York, NY 10106

Attn: Andrew Schiff
 Fax: [***]

 
 and
  

Aisling Capital III, L.P.
 888 Seventh Avenue, 30th Floor
 New York, NY 10106

Attn: Chief Financial Officer
 Fax: [***]

 
 with required copy to:

 
 McDermott Will & Emery LLP

340 Madison Avenue
 New York, NY 10173-1922

Attn: Todd Finger
 Fax: [***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	PALO ALTO PE MASTER FUND, LP
		
	By:		 /s/ Joon Yun

	 Name:     Joon Yun

Title:       General Partner

		
	Address:		 Palo Alto Investors, LLC
 470 University
Ave

	
	 Facsimile:     [***]

Email:           [***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	ADAGE CAPITAL PARTNERS, LP
		
	By:		 /s/ [illegible]

	Name:		  

	Title:		  

		
	Address:		 200 Clarendon St., 52nd Floor

Boston, MA 02116
 Attn: Dan Lehan, COO

		
	Facsimile:		  

	Email:		djl@adagecapital.com

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	LEERINK HOLDINGS LLC
		
	By:		 /s/ Joseph R. Gentile

	 Name:       Joseph R. Gentile

Title:         CAO

		
	Address:		  

			  

			  

		
	Facsimile:		[***]
	Email:		[***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	LEERINK SWANN CO-INVESTMENT FUND, LLC
		
	By:		 /s/ Joseph R. Gentile

	 Name:        Joseph R. Gentile

Title:          Manager

		
	Address:		 1 Federal Street
 Boston, MA
02110

		
	Facsimile:		  

	Email:		  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	RA CAPITAL HEALTHCARE FUND, LP
		
	By:		 /s/ Peter Kolchinsky

	Name:		Peter Kolchinsky
	Title:		Manager
		
	Address:		  

			  

			  

		
	Facsimile:		[***]
	Email:		[***]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	FIDELITY SELECT PORTFOLIOS:
	BIOTECHNOLOGY PORTFOLIO
		
	By:		 /s/ Christopher Maher

	Name:		Christopher Maher
	Title:		Assistance Treasurer
		
	Address:		  

			  

			  

		
	Facsimile:		  

	Email:		  

  
 SIGNATURE PAGE TO

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

			
	INVESTORS:
	
	 FIDELITY ADVISOR SERIES VII:

FIDELITY ADVISOR BIOTECHNOLOGY FUND

		
	By:		 /s/ Christopher Maher

	Name:		Christopher Maher
	Title:		Assistance Treasurer
		
	Address:		  

			  

			  

		
	Facsimile:		  

	Email:		  

  
 SIGNATURE PAGE TO

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 ANNEX A 

INVESTORS 
 Food Allergy
Research & Education, Inc. 
 Sunshine Charitable Foundation 

Winchester Partners, LP 
 John J. Hannan Family Trust 

DFI 2012 Growth Partnership, L.P. 
 Adam Miller 

Longitude Venture Partners II, L.P. 
 Explore Holdings LLC 

Yap Finley Family Trust 
 Foresite Capital Fund II, L.P. 

Fidelity Select Portfolios: Biotechnology Portfolio (Mag & Co.) 

Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund (Bangle & Co.) 

Aisling Capital III, LP 
 Palo Alto PE Master Fund, LP 

Adage Capital Partners, LP 
 RA Capital Healthcare Fund, LP 

Leerink Holdings LLC 
 Leerink Swann Co-Investment Fund, LLCEX-10.2

 Exhibit 10.2 

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY 

WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN 

REQUESTED WITH RESPECT TO THE OMITTED PORTION 

SUPPLY AGREEMENT 
 This
Supply Agreement (the “Agreement”) is entered into as of October 13, 2014 (the “Effective Date”) by and between Allergen Research Corporation, a California corporation, having its principal place
of business at 2000 Alameda de las Pulgas, Suite 161, San Mateo, California 94403 (“ARC”) and the Golden Peanut Company, LLC, a Georgia corporation, having its principal place of business at 100 North Point Center
East, Suite 400, Alpharetta, Georgia 30022 (together with its Affiliates and subsidiaries, collectively “Supplier”). ARC and Supplier are referred to collectively as the “Parties” and individually as a
“Party”. 
 RECITALS 

WHEREAS ARC is engaged in the research and development of immunotherapy treatments directed at peanut allergies; 

WHEREAS Supplier is in the business of supplying food-grade peanut flour; and 

WHEREAS ARC desires to engage Supplier to supply quantities of Product, as defined below, to be incorporated into ARC’s oral
immunotherapy treatment for peanut allergies, and Supplier desires to provide such supply, pursuant to the terms and conditions set forth in this Agreement. 

NOW THEREFORE, in consideration of the above premises and the mutual covenants contained herein, and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties hereto mutually agree as follows: 
 AGREEMENT 

ARTICLE I 
 DEFINITIONS 

When used in this Agreement, each of the following terms shall have the respective meanings provided below: 

Section 1.1 “Affiliate” means any corporation, firm, partnership, or other entity that controls, is controlled by, or is
under common control with a Party. For purposes of this definition, “control” shall mean the ownership of at least fifty percent (50%) of the voting share capital of such entity or any other comparable equity or ownership interest.

 Section 1.2 “Agreement Term” shall have the meaning set forth in Section 5.1. 

Section 1.3 “Applicable Law” means all laws, ordinances, rules, and regulations within the countries of the Territory
applicable to the processing and supply of Product. 
 Section 1.4 “Confidential Information” has the meaning set forth in
Section 7. below. 

 Section 1.5 “Contract Year” each individual year within the Supply Term.

 Section 1.6 “FDA” means the U.S. Food and Drug Administration, or any successor thereto. 

Section 1.7 “Field” means oral immunotherapy treatment for peanut allergy. 

Section 1.8 “First Delivery Date” has the meaning set forth in Section 2.1 below. 

Section 1.9 “Force Majeure Event” has the meaning set forth in Section 8.5 below. 

Section 1.10 “Initial Supply Term” means the time period commencing upon the First Delivery Date and continuing in
effect for a period of five (5) years. 
 Section 1.11 “Minimum Annual Volume Commitment” or “MAV
Commitment” has the meaning set forth in Section 2.4 below. 
 Section 1.12 “Product” means food-grade
peanut flour designated by Supplier’s product code [***], which [***], or any equivalent thereof that ARC requests Supplier to supply. 

Section 1.13 “Purchase Order” has the meaning set forth in Section 2.2 below. 

Section 1.14 “Renewal Term” has the meaning set forth in Section 5.1 below. 

Section 1.15 “Specifications” means the specifications for Product, attached hereto as Exhibit B, as may be amended from
time to time by mutual agreement of the Parties. 
 Section 1.16 “Supply Term” means the time period commencing
upon the first day of the Initial Supply Term and either ending upon the expiration of the Initial Supply Term or, if ARC exercises its option to renew the Agreement pursuant to Section 5.1 herein, ending upon the expiration of the Renewal
Term. 
 Section 1.17 “Territory” means the United States of America, Canada, Mexico, the European Union (which shall
include the member states of the European Union as of the Effective Date), and Japan, and any other country the Parties agree in writing to add to this definition of Territory in an amendment to this Agreement, along with any and all possessions and
territories of the foregoing countries. 
 Section 1.18 “Treatment” means ARC’s oral immunotherapy treatment for
peanut allergies. 
 ARTICLE II 

FORECASTS AND PURCHASING 

Section 2.1 On or about ninety (90) days prior to ARC’s requested date for its first delivery of Product for commercial use
(the “First Delivery Date”), ARC shall provide Supplier with a forecast of its monthly anticipated quantities of Product for the twelve (12) month period commencing upon the First Delivery Date. The parties agree that the First
Delivery Date is intended 

  
 [***] CERTAIN INFORMATION
IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY 
 WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN 

REQUESTED WITH RESPECT TO THE OMITTED PORTION 

 
to occur approximately one year prior to the date that ARC, in its good faith judgment, expects to receive approval of the Treatment from the FDA. Thereafter, by the end of each calendar quarter,
ARC shall update this forecast to cover the twelve (12) month period beginning with the next calendar quarter. For each forecast, the Product quantities set forth for the first quarter (three (3) calendar months) of the forecast period
shall be binding and the Product quantities set forth for the remaining nine months of the forecast period shall be non-binding but shall represent ARC’s best estimate of such Product quantities, using commercially reasonable efforts. For the
first forecast only, the time from the First Delivery Date to the end of the then-current calendar quarter shall be added to and considered part of the first full calendar quarter of the first forecast and
shall be binding. For clarity, if ARC reasonably expects to receive FDA approval of the Treatment on May 10,2017, (i) the First Delivery Date shall be May 10, 2016, (ii) ARC shall provide the first forecast to Supplier on or
about February 10, 2016, (iii) the first quarter of the first forecast shall begin on May 10, 2016 and end on September 30, 2016, (iv) the second quarter of the first forecast shall begin on October 1, 2016, and
(v) the first twelve (12) month forecast period shall end on June 30, 2017. For the avoidance of doubt, prior to the First Delivery Date, ARC may order small quantities of Product from Supplier for non-commercial use (including but
not limited to conducting clinical trials), and in no event shall the date of any such order or the delivery date of any such order be considered the First Delivery Date. 

Section 2.2 Together with the submission of each forecast, ARC shall submit a purchase order specifying the requested delivery dates for
the quantities of Product ARC is committing to order in the first quarter of such forecast (each, a “Purchase Order”). Supplier shall accept all Purchase Orders for a given calendar quarter that are submitted in compliance
with this Agreement. At ARC’s discretion, ARC may purchase additional quantities of Product in excess of the quantities in the forecast for such quarter. 

Section 2.3 ARC agrees to purchase from Supplier its total requirements for Product during the Agreement Term, provided that Supplier
continues to (i) supply ARC with Product conforming to the Specifications, and (ii) deliver Product conforming to the Specifications to ARC in such quantities and at such times as required by ARC. In the event that Supplier does not, or is
unable to, meet its obligations as set forth in (i) and (ii) above, ARC shall be free to purchase Product from third parties, in amounts sufficient to meet ARC’s requirements, until such time as Supplier resumes supply of Product to
ARC meeting such obligations. 
 Section 2.4 ARC hereby agrees to purchase the following minimum annual volumes of Product conforming
to the Specifications during the Supply Term (“Minimum Annual Volume Commitment” or “MAV Commitment”): 
  

			
	 Contract Year
	  	Minimum Annual Volume
	 [***]
	  	[***]

  
 [***] CERTAIN INFORMATION
IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY 
 WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN 

REQUESTED WITH RESPECT TO THE OMITTED PORTION 

 ARTICLE III 

SUPPLY AND DELIVERY 

Section 3.1 During the Agreement Term, Supplier shall supply to ARC Product conforming to the Specifications, and produced in accordance
with Applicable Law and with the terms and conditions of this Agreement, at the prices set forth in Article IV herein. 
 Section 3.2
Supplier shall maintain sufficient inventories of Product conforming to the Specifications to meet ARC’s requirements therefor. 

Section 3.3 Subject to ARC’s satisfying the conditions set forth in Section 2.3 and Section 2.4 above, Supplier hereby
agrees that it shall cease any and all sales of Product to third parties in the Territory who Supplier knows or has reason to know will use the Product within the Field, and shall not sell Product to any such third party in the Territory during the
Agreement Term. In the event that Supplier becomes aware, whether by notification from ARC or otherwise, that a third party to which Supplier has been supplying Product intends to use such Product within the Field, Supplier shall immediately cease
all sales of Product to such Third Party and shall not resume such sales for the remainder of the Agreement Term. 
 Section 3.4
Supplier shall ship the Product FOB (lncoterms 2010) Blakely, Georgia. Title in the Product shall pass to ARC when the Product is loaded on the first transportation carrier. 

Section 3.5 In the event that Supplier either (a) delivers Product that fails to conform to the Specifications, or (b) fails to
ship Product to ARC within thirty (30) days of the applicable delivery date specified on a Purchase Order accepted by Supplier, ARC shall have the right, in its sole discretion, to require either (a) a refund of the purchase price paid for
the non-conforming or undelivered Product, as applicable, or (b) the prompt replacement or delivery of such non- conforming or undelivered Product. 

ARTICLE IV 
 PRICING AND PAYMENT
TERMS 
 Section 4.1 The price for Product conforming to the Specifications shall be equal to [***] percent ([***]%) of
[***] price for such Product, attached hereto as Exhibit A. The Product price does not include any applicable excise, sales, use, withholding, luxury, turnover (value added), purchase, or similar tax of any kind. ARC shall be liable
for payment of all such taxes, fees, and charges. 
 Section 4.2 ARC hereby acknowledges that Supplier may, from time to time, make
changes to its [***] price for Product; provided, however, that (i) any such price changes shall not go into effect until January 1 of the following year and shall apply only to Purchase Orders submitted after that date, and
(ii) in no event shall Supplier make any changes to the price of Product after November 1 of any year during the Supply Term. The foregoing shall not apply to Section 4.4 herein. 

  
 [***] CERTAIN INFORMATION
IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY 
 WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN 

REQUESTED WITH RESPECT TO THE OMITTED PORTION 

 Section 4.3 Supplier shall invoice ARC for amounts due promptly after each delivery. All
invoices shall be due and payable thirty (30) days from the date of the applicable invoice; 
 provided, however, that Supplier may change the
foregoing time period upon advance written notice to ARC in the event that ARC’s credit or financial responsibility has become, in Supplier’s discretion, unsatisfactory. In the event any payments become past due, such overdue amounts shall
be subject to interest accrued at an annual rate equal to the maximum interest rate permitted by law. 
 Section 4.4 In the event that
ARC fails to satisfy the applicable MAV Commitment in a given Contract Year, Supplier shall (i) be relieved of the obligations set forth in Section 3.3 herein, and (ii) have the option to renegotiate the Product pricing applicable to
ARC. 
 ARTICLE V 
 TERM AND
TERMINATION 
 Section 5.1 The term of the Agreement will commence as of the Effective Date and, unless earlier terminated pursuant to
this Article 5, shall continue until the expiration of the Initial Supply Term (“Agreement Term”). Upon expiration of the Initial Supply Term, ARC shall have the option to renew the Agreement for an additional term of
five (5) years by written notice to Supplier provided prior to the expiration of the Initial Supply Term (the “Renewal Term”), in which case the Agreement Term shall continue until expiration of the Renewal Term, unless
earlier terminated pursuant to this Article 5, provided that ARC’s option for a Renewal Term shall be void if ARC has not complied with the terms and conditions set forth in this Agreement, including but not limited to ARC’s satisfaction
of the MAV Commitments set forth in Section 2.4. 
 Section 5.2 ARC may terminate the Agreement at will at any time, for any
reason, upon sixty (60) days’ advance written notice to Supplier. 
 Section 5.3 Supplier may terminate this Agreement in its
entirety upon sixty (60) days’ advance written advance in the event that ARC fails to satisfy the applicable MAV Commitment in a given Contract Year in any material respect, unless ARC pays to Supplier at any time prior to the expiration
of such sixty (60) day period, an amount equal to the difference between the volume of Product that would have been purchased if ARC met the MAV Commitment in such Contract Year, and the volume of Product actually purchased by ARC in such
Contract Year, multiplied by Supplier’s [***] price for Product. 
 Section 5.4 This Agreement may be terminated in its
entirety by either Party immediately upon written notice upon the occurrence of any of the following events: 
 (a) A Party’s material
breach of any representation, warranty, covenant, or obligation contained in this Agreement (other than with respect to the MAV Commitment) that is not excused by a Force Majeure Event and is not cured within thirty (30) days’ of receiving
written notice from the non-breaching Party setting forth the details of such breach; 

  
 [***] CERTAIN INFORMATION
IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY 
 WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN 

REQUESTED WITH RESPECT TO THE OMITTED PORTION 

 (b) Due to a Force Majeure Event, a Party fails to fulfill any of its obligations under this
Agreement for a continuous period of ninety (90) days or more; or 
 (c) The other Party (i) becomes insolvent, (ii) makes an
assignment for the benefit of creditors, (iii) files a voluntary petition in bankruptcy, (iv) an involuntary petition inbankruptcy filed against it and is not dismissed within ninety (90) days of filing, or (v) has a receiver
appointed for a substantial portion of its assets. 
 Section 5.5 Upon termination or expiration of this Agreement, Supplier shall
(i) fulfill any Purchase Orders accepted prior to such termination or expiration, if such termination is not due to ARC’s material breach or failure to meet the MAV Commitment, (ii) cease any ongoing production of Product intended for
fulfillment of any subsequent purchase orders expected pursuant to forecasts received prior to such termination or expiration, and (iii) limit further expenses associated with such ongoing production. Following any termination or expiration of
this Agreement, ARC shall be liable for the following (as invoiced by Supplier): (i) all orders produced or in production on behalf of ARC pursuant to a Purchase Order, (ii) all expenses incurred or committed by Supplier on ARC’s
behalf. 
 Section 5.6 Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued
to the benefit of either Party prior to such expiration or termination, including without limitation ARC’s payment obligations to Supplier. Termination of this Agreement for any reason shall not affect any obligations which, from the context
hereof, are intended to survive termination of this Agreement. 
 ARTICLE VI 

REPRESENTATIONS, WARRANTIES, AND COVENANTS 

Section 6.1 Supplier represents, warrants, and covenants as follows: 

(a) All Product delivered hereunder shall, at the time of shipment, be free and clear of any liens or encumbrances, and shall conform to the
Specifications; 
 (b) All Product delivered hereunder shall be produced in compliance with all Applicable Laws, including without
limitation the Fair Labor Standards Act of 1938, as amended; and 
 (c) To Supplier’s knowledge, the manufacture, use and sale of the
Product does not and will not infringe upon any third party’s intellectual property. 
 Section 6.2 ARC represents, warrants and
covenants that the Product will be used by it in a manner that complies with the laws, rules, and regulations of any governmental regulatory authority within the Territory involved in regulating any aspect of the development, manufacture, market
approval, sale, distribution, packaging, or use of drug products, including, but not limited to, the FDA, the Canadian Health Products and Food Branch, and The European Agency for the Evaluation of Medicinal Products. 

 Section 6.3 Each Party represents, warrants, and covenants that, as of the Effective Date,
it: 
 (a) is a corporation duly organized and validly existing and in good standing under the laws of its jurisdiction of the organization;

 (b) is qualified or licensed to do business and in good standing in every jurisdiction where such qualification or licensing is required;

 (c) has the corporate power and authority to negotiate, execute, deliver, and perform its obligations under this Agreement; 

(d) has no obligations or commitments to third parties inconsistent or in conflict with this Agreement and, during the Agreement Term, will
not enter into any obligations or commitments to third parties inconsistent with or in conflict with this Agreement; and 
 (e) has secured
all consents and authorizations necessary to enter into this Agreement and proceed with the undertakings required herein and the execution, delivery and performance of this Agreement have been duly and validly authorized. 

Section 6.4 For the avoidance of doubt, it is ARC’s sole responsibility to determine the suitability of the Product for use in the
Field and Supplier shall have no responsibilities in relation thereto hereunder. 
 Section 6.5 EXCEPT AS EXPRESSLY PROVIDED HEREIN,
SUPPLIER EXPRESSLY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED, OR STATUTORY, AS TO ANY GOODS DELIVERED IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

ARTICLE VII 
 CONFIDENTIALITY 

Section 7.1 The terms of this Agreement and any confidential or proprietary information or trade secrets disclosed by either Party to the
other prior to or during the Agreement Term (collectively, the “Confidential Information”) shall be treated as confidential. 

Section 7.2 Except as expressly permitted under this Agreement, each Party agrees that, during the Agreement Term, and for a period of
five (5) years thereafter, it shall: 
 (a) Use the Confidential Information only for the purpose of satisfying its obligations under
this Agreement; and 
 (b) Not disclose the Confidential Information to any third party. 

Section 7.3 The restrictions in this Article VII shall not apply to any Confidential Information the receiving Party can demonstrate:

 (a) is or has become publicly available through no fault of the receiving Party or its employees; 

 (b) is received from a third party lawfully in possession of such information and lawfully
empowered to disclose such information; 
 (c) was rightfully in the possession of the receiving Party prior to its disclosure by the
disclosing Party, as evidenced by written records of the receiving Party; or 
 (d) is independently developed by employees or consultants
of the receiving Pa1ty without use of Confidential Information of the disclosing Party, as evidenced by written records of the receiving Party. 

Section 7.4 Notwithstanding the foregoing, each Party may disclose the other Party’s Confidential Information to any of its
Affiliates, officers, directors, employees, agents, and representatives, that (i) need to know such Confidential Information for the purpose of performing under this Agreement, (b) are advised of the contents of this Article, and
(c) are bound by confidentiality and non-use obligations equivalent to those in this Article VII. Additionally, each Party may disclose the other Party’s Confidential Information to the extent the other Party provides its written consent
to such disclosure, such consent not to be unreasonably withheld. 
 Section 7.5 Notwithstanding the foregoing, the receiving Party may
disclose Confidential Information pursuant to the lawful requirement or request of a governmental agency or otherwise required to be disclosed by law, rule, regulation, or rules of a securities exchange, provided that where available, reasonable
measures are taken to obtain confidential treatment thereof and to guard against further disclosure, and further provided that where practicable, reasonable written notice is provided to the disclosing Party to enable the disclosing Party to seek
protection of the confidentiality of such Confidential Information, with which the receiving Party shall assist in any reasonable way. 

Section 7.6 Upon termination or expiration of this Agreement, the receiving Party shall cease all use of the Confidential Information of
the disclosing Party (except as otherwise provided in this Agreement) and, upon request, shall either (a) promptly return within thirty (30) days all such Confidential Information, including any copies thereof, or (b) promptly destroy
all such Confidential Information and certify such destruction to the disclosing Party; provided, however, that the receiving Party may retain a single copy thereof for the sole purpose of determining the scope of the obligations incurred under this
Agreement. 
 ARTICLE VIII 

MISCELLANEOUS 
 Section 8.1
Assignment or Transfer. Neither Party may assign this Agreement or any of its rights and obligations thereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that
either Party may assign its rights and obligations under the Agreement to an Affiliate or subsidiary of such Party, and further provided that either party may assign this Agreement to any party that acquires either all or substantially all of the
stock of such party or such party’s assets and operations related to the purpose of this Agreement. Any assignments or transfers in violation of this Section 8.1 shall be void. This Agreement shall be binding on any successors or assignees
authorized by this Section 8.1. 

 Section 8.2 Indemnification; Limitations of Liability. Each Party shall indemnify,
defend, and hold harmless the other party from and against any loss, liability, claim, or action (whether or not meritorious), to persons, property, or third parties (“Loss”), to the extent that such Loss (a) arises out of the breach
of any of the warranties set forth in this Agreement; or (b) was caused by the negligence or intentional wrongdoing of the indemnifying party or its agents, subcontractors, or Affiliates. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY
UNDER THIS AGREEMENT FOR ANY INDIRECT, CONSEQUENTIAL, PUNITIVE, SPECIAL, OR INCIDENTAL DAMAGES. 
 Section 8.3 Insurance.
During the Agreement Term, each Party shall maintain workers’ compensation insurance with limits of not less than two million ($2,000,000) dollars per occurrence and two million ($2,000,000) dollars in the aggregate, and commercial general
liability insurance with limits of not less than one million ($1,000,000) dollars per occurrence and two million ($2,000,000) dollars in the aggregate. 

Section 8.4 Expenses. Each Party shall be responsible for any costs and expenses, including professional fees, that such Party
incurs in connection with performing its obligations under this Agreement. 
 Section 8.5 Force Majeure. If a Party is delayed
in fulfilling any of the terms and conditions hereunder due to acts of God, war, prohibitions on exports or imports, fires, floods, strikes, sabotage, civil commotion or riots, earthquakes, or any other cause beyond such Party’s reasonable
control (each a “Force Majeure Event”), time for such performance by such Party shall be extended by the period of time equal to that caused by such delay in performance. Once the Force Majeure Event ceases to exist, all
terms and conditions of this Agreement will again prevail. The foregoing is subject to the right of termination set forth in Section 5.4(b) herein. 

Section 8.6 Nature of Relationship. Nothing in this Agreement shall be deemed or construed to constitute or create between the
Parties hereto a partnership, joint venture or agency. Neither ARC nor Supplier shall engage in any conduct that might create the impression or inference that ARC or Supplier, as applicable, is a partner, joint venturer, or officer of the other.
Supplier hereby certifies that it is engaged in an independent business and will perform its obligations under this Agreement as an independent contractor and not as the agent or employee of ARC. 

Section 8.7 Separability of Clauses. Any provision or provisions of this Agreement that in any way contravene the law of any state
or country in which this Agreement is effective shall, in such state or country, to the extent of such contravention of law, be deemed separable and shall not affect any other provisions hereof or the validity hereof. 

Section 8.8 Notices. All notices and other communications hereunder shall be in writing and sent to the applicable address set
forth below, or to another address if specified by 

 
Zlike notice, and shall be deemed given when, as applicable: (a) delivered personally; (b) delivered by facsimile transmission (receipt verified); or (c) received or refused, if
mailed by registered or certified mail (return receipt requested), postage prepaid, or reliable overnight courier service; provided, however, that notices of a change of address shall be effective only upon receipt thereof: 

 

			
	If to ARC:		Allergen Research Corporation
			2000 Alameda de las Pulgas, Suite 161
			San Mateo, CA 94403
			Attn: Howard V. Raff, Ph.D.
			Fax: (650) 393-5471
		
	If to Supplier:		Golden Peanut Company, LLC,
			100 North Point Center East, Suite 400
			Alpharetta, GA 30022
			Attn: President
			Fax: (770) 752-8209

 Section 8.9 Entire Agreement. This Agreement, together with all attachments hereto, sets forth the
entire agreement and understanding between the Parties on the subject matter thereof, and merges all prior discussions and negotiations between them. Neither of the Parties shall be bound by any conditions, definitions, representations, or
warranties with respect to the subject matter of this Agreement other than as expressly provided herein or as duly set forth on or subsequent to the date hereof in a writing signed by duly authorized representatives of both Parties. This
Agreement cannot be modified or amended through statements appearing on any Purchase Order or invoice. 
 Section 8.10 Governing
Law. This Agreement and its formation, operation, and performance shall be governed, construed, performed, and enforced in accordance with the substantive laws of the State of Illinois, without regard to its conflict of laws principles.
Exclusive jurisdiction for litigation of any dispute, controversy, or claim arising out of or in connection with this Agreement, or breach thereof shall be only in the Federal or State court with competent jurisdiction located in Cook County,
Chicago, Illinois. 
 Section 8.11 Paragraph Headings. Paragraph headings have been inserted solely for the convenience of the
Parties and shall not be considered a part of this Agreement for interpretation or construction. 
 Section 8.12 Publicity.
Neither Party shall use the other Party’s name or trademarks in any advertising, promotional efforts, or publicity of any kind without the prior written permission of such Party, except as required under Applicable Law, in which case the Party
required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the other Party as to the form, nature, and extent of the press release or public disclosure prior to issuing the press
release or making the public disclosure. 
 Section 8.13 Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original. 

 Section 8.14 Waiver. No waiver of any provision of this Agreement or any right or
obligation of a Party shall be effective unless in writing and signed by the Parties. The failure of either Party to enforce a right shall not constitute a waiver. 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date.

  

									
	SUPPLIER:				ARC:
					
	By:		 /s/ Kris Luft
				By:		 /s/ Stephen Dilly

	Name:		Kris Luft				Name:		Stephen Dilly
	Title:		President				Title:		C.E.O.

 EXHIBIT A 

Pricing 
 See Section 4.1 

Exhibit A-1 

 SPECIALTY PRODUCTS 

PRICE LIST 
 [***] PEANUT FLOUR – [***]

 Product Codes: [***] 
  

					
	 VOLUME:
	  	 PER POUND
	  	 
	[***]	  	$[***]	  	

  

					
		
	PACKAGING:	  	50 lb. (22.68 kilo) multiwall paper bags — 40 bags (2,000 lbs.) / pallet
			
	FREIGHT CONDITIONS:	  	Freight collect. F.O.B. Blakely, GA 39823	  	
			
	TERMS:	  	Net 30 days with approved credit	  	
			
	SAMPLE SIZE:	  	1 lb. {0.45 kg)	  	
			
	[***]	  		  	01 /14

  
  

					
	

	  	 100 North Point Center East

Suite 400
 Alpharetta, Georgia
30022
 (770) 752-8190
 (770)
752-8209 Fax www.goldenpeanut.com
	  	

  
 [***] CERTAIN INFORMATION
IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY 
 WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN 

REQUESTED WITH RESPECT TO THE OMITTED PORTION 

 EXHIBIT B 

Product Specifications 

SPECIALTY PRODUCTS 
 [***]
PEANUT FLOUR – [***] 
 Product Code [***] 

DESCRIPTION: 
 [***] Peanut Flour is made from
high oleic raw peanuts, which have been cleaned, blanched, and electronically sorted to select the highest quality peanuts. The nuts are then roasted and processed through a natural process to obtain a peanut flour with a controlled fat content.
Peanut flour is gluten-free. High oleic peanuts are much more stable than traditional peanuts resulting in a more stable peanut flour. 
  

															
	FLAVOR:		[***]												
							
	SUGGESTED APPLICATIONS:												
	 Confections
				[***]				 Sauces
				
	 Baked Goods
				Nutritional Bars				 Fillings
				
							
	INGREDIENT DECLARATION:		 Peanuts- 100%
										
		
	LABEL DECLARATION:		 Peanut Flour, [***], Peanuts, Roasted Peanuts, Roasted

Peanut Flour, [***]

	TYPICAL ANALYSIS:														
	[***]				   [***]
				[***]				[***]		
			
	PACKAGING:		50 lb. (22.7 kg.) multi-wall paper- poly lined bags- 40 bags/pallet		
								
	SAMPLE SIZE:		11b.		 KOSHER:
		OU		HALAL:		I.S.A.				
			
	STORAGE CONDITIONS:		 Cool/ Dry-refrigerated preferred
		
			
	SHELF LIFE:		 Under refrigeration: 9 – 12 months

If not stored under refrigeration, product must be sensory tested prior to each use.
		
							
	Country of Origin:		Product of USA										
						
	This information contained herein is correct to the best of our knowledge. The recommendations or suggestions contained in this bulletin are made without guarantee or representation as to results. We suggest that you
evaluate these recommendations and suggestions in your own laboratory prior to use. Our responsibility for claims arising from breach of warranty, negligence, or otherwise is limited to the purchase price of the material. Freedom to use any										

  
  

 

					
	 

		 100 North Point Center East

Suite 400
 Alpharetta, Georgia
30022
 (770) 752-8190
 (770)
752-8209 Fax www.goldenpeanut.com
		

  
 [***] CERTAIN INFORMATION
IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY 
 WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN 

REQUESTED WITH RESPECT TO THE OMITTED PORTION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]